Compare DSAC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DSAC | VCRE |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United Kingdom | Sweden |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.6M | 316.4M |
| IPO Year | 2025 | 2026 |
| Metric | DSAC | VCRE |
|---|---|---|
| Price | $10.17 | $10.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 238.2K | 10.3K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $10.16 |
| 52 Week High | $10.47 | $13.15 |
| Indicator | DSAC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 35.77 |
| Support Level | $9.90 | N/A |
| Resistance Level | $10.18 | $13.00 |
| Average True Range (ATR) | 0.01 | 0.54 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 16.67 | 14.15 |
Daedalus Special Acquisition Corp is a blank check company.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.